ASCO has released a clinical practice guideline on invasive cervical cancer. For the first time, ASCO created the guideline based on resource availability, tailoring recommendations to support basic- or limited-resource settings.
A concurrent chemotherapy and radiotherapy regimen with cisplatin and paclitaxel yielded a good response rate and strong long-term survival outcomes in patients with locally advanced or recurrent cervical cancer.
A live attenuated bioengineered bacteria-vectored vaccine immunotherapy is well tolerated and appears to be associated with promising overall survival among women with persistent/recurrent metastatic cervical cancer.
Don Dizon, MD, Brown University, discusses the paradigm shift in the treatment of endometrial cancer with the use of medical therapy, including chemotherapy with biologics, mTOR inhibitors combined with chemotherapy, and targeted therapies.